Products in pipeline

reMYND's pre-clinical pipeline of small molecules consists primarily of:

  • 2 disease-modifiers for treating Alzheimer's disease (counteracting tau-toxicity)
  • 2 disease-modifiers for Diabetes mellitus type II
  • 1 disease-modifiers for treating Parkinson's disease (counteracting α-synuclein toxicity)
  • 1 disease-modifier for Epilepsy
  • and disease-modifiers targeting orphan diseases

For further information, please contact pipeline@remynd.com